Lupus Foundation of America Greater Ohio Chapter Logo

Toll Free: 1 (888) NO-LUPUS
Phone: (440) 717-0183

Help Us Solve The Cruel MysteryTM

Donate To The Ohio Chapter

Update: Investigational Therapy CABA-201 for Lupus Treatment Shows Positive Initial Data

by | Jun 19, 2024

Inside Lupus Research (ILR): Treatment News

Initial Phase 1 of 2 RESET-Myositis and RESET-SLE clinical trial data of the investigational therapy, CABA-201, revealed positive outcomes. The first two study participants did not exhibit infections or serious adverse events and complete B cell depletion was observed in both participants after 15 days of treatment. Additionally, at week 4, the SLE study participant demonstrated an improvement in disease activity. 

CABA-201 is a CAR T-cell therapy designed to target B cells that is being explored as a possible treatment for systemic lupus erythematosus (SLE) and lupus nephritis (LN, lupus-related kidney disease) . CABA-201 is given as a one-time IV– infusion. 

Participants are being recruited for the Phase 1/2 RESET™ trials across 18 sites. Five people have enrolled as of June 12, 2024. Continue to follow the Lupus Foundation of America for CABA-201 updates, as well as other lupus drug development news, and learn about medications used to treat lupus.

Read the announcement

This post was originally published on this site

Skip to content